During his tenure as President of the global vaccine business of Wyeth Pharmaceuticals (1986-1999), the company introduced several new vaccine products, including Prevnar, HibTiter, Tetramune, Acel-Imune, PnuImune 23, Menigicoccus C conjugate and Rotavirus.  Subsequent to his retirement,Dr. Saldarini founded Biological Initiatives, a private consulting firm providing service to the vaccines and pharmaceutical industry.  Until September, 2009, when the sale of Medarex to Bristol Myers (BMS) was concluded he served as Lead Director of Medarex, Inc.  He is Second Vice Chairman and member of the Board of Trustees of  Community Blood Services of Paramus, N.J. where he the Chairman of the New Jersey Umbilical Cord Blood Bank Scientific & Medical Advisory Panel. He is a member of the Scientific Advisory Board of CTI Life Sciences.  He is an associate at Naimark & Associates, consultants to the healthcare industry.   He has been Chairman and member of the following boards, Idun Pharmaceuticals until its sale to Pfizer Inc. in 2006, Therion Biologicals, Alphavax, Inc., and Medavante, Inc.  He also was a director of Cellegy Pharmaceuticals, Inc.  He has served as a consultant several vaccine companies, on four committees of the National Academy of Sciences Institute of Medicine, the Malaria Vaccine Initiative and has been a member of several committees/boards as the National Vaccine Advisory Commission, The Blue Ribbon Search Committee for the selection of the Food and Drug Administration Commissioner, the Board of Trustees of the National Foundation of Infectious Disease, the Immunization Advisory Council of the New York Department of Health, the Policy Board of the Albert B. Sabin Vaccine Foundation,  and the Corporate Council for the Childrens Health Fund.  Dr. Saldarini has a B.A from Drew University and a Ph.D. from the University of Kansas.